Safinamide (INN; brand name Xadago, former developmental code name EMD-1195686) is a drug indicated for the treatment of Parkinson's disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally discovered at Farmitalia-Carlo Erba, first published in 1998 and developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.

CAS：202825-46-5
中文别名：马波沙星,麻保沙星;
英文别名：Safinamide Mesylate;(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide,methanesulfonic acid;(S)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide,methanesulfonate;(S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide;PNU-151774E,NW-1015;FCE-28073(R-isomer),PNU-151774E,NW-1015;(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide;
分子式：C18H23FN2O5S
分子量：398.449
精确质量：398.131
Psa：127.1
Logp：4.0441

MDL号：MFCD15145475

沸点：476.7ºC at 760 mmHg
闪点：242.1ºC
蒸汽压：2.98E-09mmHg at 25°C

海关编码：2924299090
危险标志：GHS05, GHS06, GHS09
危险性描述：H301; H318; H400
危险性防范说明：P273; P280; P301 + P310; P305 + P351 + P338
信号词：Danger